Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19

NACompletedINTERVENTIONAL
Enrollment

448

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

September 9, 2022

Study Completion Date

November 30, 2022

Conditions
Covid19Pregnancy RelatedMaternal Complication of PregnancyCoronavirusNeonatal InfectionPrenatal StressPreterm Birth
Interventions
DIAGNOSTIC_TEST

Antibody testing for SARS-CoV-2 IgG

Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization.

DIAGNOSTIC_TEST

Testing for SARS-CoV-2 RNA

Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available.

DIAGNOSTIC_TEST

Testing for SARS-CoV-2 IgM/IgG

Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available.

Trial Locations (1)

63110

Washington University Medical Center, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mercy Research

OTHER

lead

Washington University School of Medicine

OTHER